Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Gonzalez-Cao, M; Puertolas, T; Martinez-Vila, C; Carrera, C; Seral, CM; Rodriguez-Jimenez, P; Sequero, S; Cerezuela-Fuentes, P; Ochoa, RF; Munoz, E; Basa, MA; Martin-Liberal, J; Soria, A; Moreno, JFR; Marquez-Rodas, I; Criado, PL; Manzano, JL; Lopez-Castro, R; De Miguel, PA; Villalobos, L; Algarra, SM; Gonzalez-Barrallo, I; Boada, A; Castano, AG; Puig, S; Crespo, G; Fra, PL; Zamora, CA; Rodriguez, MF; Valles, L; Drozdowskyj, A; Gardeazabal, J; Fernandez-Morales, LA; Rodrigo, A; Cruz, R; Yelamos, O; Rubio, B; Mujica, K; Provencio, M; Berrocal, A.

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Clinical & Translational Oncology. 2023; 25(3): 768-775 Nº de citas: 2 [doi:10.1007/s12094-022-02985-7]

Wong, SK; Blum, SM; Sun, XP; Da Silva IP; Zubiri, L; Ye, F; Bai, K; Zhang, KV; Ugurel, S; Zimmer, L; Livingstone, E; Schadendorf, D; Serra-Bellver, P; Muñoz-Couselo E; Ortiz, C; Lostes, J; Huertas, RM; Arance, A; Pickering, L; Long, GV; Carlino, MS; Buchbinder, EI; Vazquez-Cortes, L; Jara-Casas, D; Marquez-Rodas, I; Gonzalez-Espinoza, IR; Balko, JM; Menzies, AM; Sullivan, RJ; Johnson, DB.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

EUROPEAN JOURNAL OF CANCER. 2023; 181: 188-197 Nº de citas: 14 [doi:10.1016/j.ejca.2022.12.013]

Toledano-Fonseca, M; Gomez-Espana, MA; Elez, E; Gravalos, C; Garcia-Alfonso, P; Rodriguez, R; Losa, F; Diaz, IA; Grana, B; Valladares-Ayerbes, M; Garcia-Ortiz, MV; Polo, E; Salgado, M; Rivera, F; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, JM; Riesco, MC; Rodriguez-Ariza, A; Aranda, E.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

BIOMEDICINE & PHARMACOTHERAPY. 2023; 159: Nº de citas: 10 [doi:10.1016/j.biopha.2023.114272]

Herzog, TJ; Pignata, S; Ghamande, SA; Rubio, MJ; Fujiwara, K; Vulsteke, C; Armstrong, DK; Sehouli, J; Coleman, RL; Gabra, H; Scambia, G; Monk, BJ; Arranz, JA; Ushijima, K; Hanna, R; Zamagni, C; Wenham, RM; Gonzalez-Martin, A; Slomovitz, B; Jia, Y; Ramsay, L; Tewari, KS; Weil, SC; Vergote, IB.

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Gynecologic Oncology. 2023; 170: 300-308 Nº de citas: 18 [doi:10.1016/j.ygyno.2023.01.003]

Andric Z; Gálffy G; Cobo Dols M; Szima B; Stojanovic G; Petrovic M; Felip E; Vicente Baz D; Ponce Aix S; Juan-Vidal O; Szalai Z; Losonczy G; Calles Blanco A; Bernabe R; García Ledo G; Aguilar Hernández A; Duecker K; Zhou D; Schroeder A; Guezel G; Ciardiello F.

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

JTO Clinical and Research Reports. 2023; 4(2): 100461-100461 Nº de citas: 1 [doi:10.1016/j.jtocrr.2022.100461]

Bar J; Peled N; Schokrpur S; Wolner M; Rotem O; Girard N; Aboubakar Nana F; Derijcke S; Kian W; Patel S; Gantz-Sorotsky H; Zer A; Moskovitz M; Metro G; Rottenberg Y; Calles A; Hochmair M; Cuppens K; Decoster L; Reck M; Limon D; Rodriguez E; Astaras C; Bettini A; Häfliger S; Addeo A.

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Journal of Thoracic Oncology. 2023; 18(2): 169-180 Nº de citas: 85 [doi:10.1016/j.jtho.2022.10.004]

Vazquez, JC; Pinero, A; de Castro, FJ; Lluch, A; Martin, M; Barnadas, A; Alba, E; Rodriguez-Lescure, A; Rojo, F; Gimenez, J; Sola, I; Quintana, MJ; Bonfill, X; Urrutia, G; Sanchez-Rovira, P.

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

Clinical & Translational Oncology. 2023; 25(2): 417-428 Nº de citas: 4 [doi:10.1007/s12094-022-02953-1]

Asleh, K; Lluch, A; Goytain, A; Barrios, C; Wang, XQ; Torrecillas, L; Gao, DX; Ruiz-Borrego, M; Leung, S; Bines, J; Guerrero-Zotano, A; Garcia-Saenz, JA; Cejalvo, JM; Herranz, J; Torres, R; de la Haba-rodriguez, J; Ayala, F; Gomez, H; Rojo, F; Nielsen, TO; Martin, M.

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

CLINICAL CANCER RESEARCH. 2023; 29(2): 389-400 Nº de citas: 23 [doi:10.1158/1078-0432.CCR-22-2191]

Vidal, J; Fernandez-Rodriguez, MC; Casadevall, D; Garcia-Alfonso, P; Paez, D; Guix, M; Alonso, V; Cano, MT; Santos, C; Duran, G; Elez, E; Manzano, JL; Garcia-Carbonero, R; Ferreiro, R; Losa, F; Pineda, E; Sastre, J; Rivera, F; Bellosillo, B; Tabernero, J; Aranda, E; Salazar, R; Montagut, C.

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

CLINICAL CANCER RESEARCH. 2023; 29(2): 379-388 Nº de citas: 38 [doi:10.1158/1078-0432.CCR-22-1696]

de Haas, SL; Slamon, DJ; Martin, M; Press, MF; Lewis, GD; Lambertini, C; Prat, A; Lopez-Valverde, V; Boulet, T; Hurvitz, SA.

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine plus pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

BREAST CANCER RESEARCH. 2023; 25(1): Nº de citas: 42 [doi:10.1186/s13058-022-01587-z]

Molpeceres, C; Ramos-Medina, R; Marquez, A; Romero, P; Gomez-Fontela, M; Candorcio-Simon, R; Munoz, A; Lauzurica, S; del Monte-Millan, M; Morales, M; Munoz-Martin, D; Lopez-Tarruella, S; Massarrah, T; Martin, M.

Laser transfer for circulating tumor cell isolation in liquid biopsy

International Journal of Bioprinting. 2023; 9(4): Nº de citas: 6 [doi:10.18063/ijb.720]

Presa, M; Vicente, D; Calles, A; Salinas-Ortega, L; Naik, J; García, LF; Soto, J.

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

ClinicoEconomics and Outcomes Research. 2023; 15: 659-671 Nº de citas: 6 [doi:10.2147/CEOR.S415711]

Galera, M; Alvarez, R; Arregui, M; Paniagua, M; Alvarez, A; Crisostomo, RAG; Díazgranados, A; Gutiérrez, N; Calles, A; Agra, C.

A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin

Case Reports in Oncology. 2023; 16(1): 1542-1550 Nº de citas: 2 [doi:10.1159/000534935]

Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B.

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.

Revista Espanola de Patologia. 2023; 56(1): 32-44 [doi:10.1016/j.patol.2022.06.004]

Jimenez-Fonseca, P; Foy, V; Raby, S; Carmona-Bayonas, A; Macia-Rivas, L; Arrazubi, V; Lavin, DC; Gil, RHS; Custodio, A; Cano, JM; Montes, AF; Mirallas, O; Declara, IM; Tocino, RV; Visa, L; Limon, ML; Pimentel, P; Lago, NM; Sauri, T; Richard, MM; Mangas, M; Raga, MG; Calvo, A; Reguera, P; Granja, M; Carnicero, AM; Perez, CH; Cerda, P; Gonzalez, LG; Navalon, FG; Barcia, VP; Abad, D; Martin, MR; Weaver, J; Mansoor, W; Gallego, J.

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 2 [doi:10.1177/17588359231157641]

Perez-Fidalgo, JA; Ortega, E; Ponce, J; Redondo, A; Sevilla, I; Valverde, C; Verdum, JI; de Alava, E; Lopez, MG; Marquina, G; Sebio, A.

Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 34 [doi:10.1177/17588359231157645]

Arance, A; De La Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Marquez-Rodas, I; Spreafico, A; Atkinson, V; Costa Svedman F; Mant, A; Khattak, MA; Mihalcioiu, C; Jang, S; Cowey, CL; Smith, AD; Hawk, N; Chen, K; Diede, SJ; Krepler, C; Long, GV.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(1): 75-85 Nº de citas: 105 [doi:10.1200/JCO.22.00221]

Johnston SRD; Toi, M; O'Shaughnessy, J; Rastogi, P; Campone, M; Neven, P; Huang, CS; Huober, J; Jaliffe, GG; Cicin, I; Tolaney, SM; Goetz, MP; Rugo, HS; Senkus, E; Testa, L; Del Mastro, L; Shimizu, C; Wei, R; Shahir, A; Munoz, M; San Antonio, B; André V; Harbeck, N; Martin, M.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

LANCET ONCOLOGY. 2023; 24(1): 77-90 Nº de citas: 509 [doi:10.1016/S1470-2045(22)00694-5]